Upgrade to SI Premium - Free Trial

Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight

November 16, 2016 7:34 AM

Morgan Stanley downgraded Teva Pharma (NYSE: TEVA) from Overweight to Equalweight with a price target of $42.00 (from $63.00).

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $37.60 yesterday.

Categories

Analyst PT Change Downgrades

Next Articles